Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of December 2025, specifically detailing a share repurchase executed on December 4, 2025. The company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow). Key metrics for the transaction are as follows:
- Date of Purchase: December 4, 2025
- Shares Purchased: 233,000 ordinary shares
- Price Range: Lowest 1,819.00p; Highest 1,852.50p
- Volume-Weighted Average Price (VWAP): 1,832.36p
- Broker: BNP Paribas SA
- Trading Venues: London Stock Exchange (XLON), CHIX, and BATE
Since the commencement of the current buyback programme on September 30, 2025, GSK has purchased an aggregate of 11,997,733 ordinary shares.
Material Changes and Capital Structure
Following the December 4 transaction, the company's capital structure has been updated as follows:
- Treasury Shares Held: 237,462,577 ordinary shares
- Shares in Issue (excluding Treasury): 4,077,971,107 ordinary shares
- Total Voting Rights: 4,077,971,107
- Treasury Share Voting Percentage: 5.82% of total voting rights
The purchased shares are held as Treasury shares. The filing notes that the total number of voting rights may be used by shareholders as the denominator for calculating notification thresholds under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing confirms that the purchase was effected pursuant to a non-discretionary agreement entered into with the broker on September 30, 2025. No new financial guidance or operational outlook is provided in this specific document.
Risk Factors: The filing includes a standard cautionary statement regarding forward-looking statements. It notes that actual results may differ materially from projections due to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q3 Results for 2025.
Investor Verification Checklist
- Verify the total number of shares held in treasury (237,462,577) against the company's latest capitalization table.
- Confirm the remaining capacity under the non-discretionary buyback agreement announced on September 30, 2025.
- Review the "Risk Factors" in the 2024 Form 20-F and Q3 2025 results for context on the company's broader financial health, as this filing contains no operational data.
- Monitor the 5.82% treasury share voting percentage for potential impacts on shareholder notification thresholds.